SCHEMBL3494404

SCHEMBL3494404

Cc1ccccc1Cc1nc2sc(C(=O)O)c(C)c2c(=O)[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.61
ALDH1A1 P00352 11/20 0.60
KMT2A Q03164 9/20 0.60
KDM4E B2RXH2 2/20 0.60
MEN1 O00255 6/20 0.55
POLB P06746 6/20 0.55
TDP1 Q9NUW8 5/20 0.55
MCL1 Q07820 2/20 0.55
HPGD P15428 1/20 0.55
APEX1 P27695 1/20 0.55
RECQL P46063 1/20 0.55
L3MBTL1 Q9Y468 4/20 0.54
USP2 O75604 1/20 0.53
THRB P10828 1/20 0.53
APOBEC3A P31941 1/20 0.53
APOBEC3G Q9HC16 1/20 0.53
LMNA P02545 1/20 0.53
HTT P42858 1/20 0.48
GAA P10253 1/20 0.48
BLM P54132 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3490758 0.90 ALDH1A1 (0.59) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL3493776 0.89 ALDH1A1 (0.58) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL3490635 0.89 ALDH1A1 (0.58) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL3492677 0.88 MAPT (0.61) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL13341339 0.88 ALDH1A1 (0.75) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL3493917 0.88 KMT2A (0.57) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL3491611 0.87 KMT2A (0.56) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL4519184 0.87 KMT2A (0.68) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL3494121 0.86 KMT2A (0.55) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL3494401 0.85 ALDH1A1 (0.57) MAPTALDH1A1KMT2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870656-B2 Methods for treatment of heart failure CARDURION PHARMACEUTICALS, LLC (US) 2020-12-22 US disclosed
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE CARDURION PHARMACEUTICALS LLC (US) 2019-07-11 US disclosed
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD MAPT 1324/4885ALDH1A1 762/4885KMT2A 2820/4885
US-10870656-B2 Methods for treatment of heart failure TNNT2, TNNI3, TNNC1 MAPT 4634/4885ALDH1A1 748/4885KMT2A 3654/4885
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 MAPT 1619/4885ALDH1A1 2303/4885KMT2A 2650/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 MAPT 1619/4885ALDH1A1 2303/4885KMT2A 2650/4885
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE TNNT2, TNNI3, TNNC1 MAPT 4634/4885ALDH1A1 748/4885KMT2A 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.